Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Refractory period

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    959 result(s) found for: Refractory period. Displaying page 1 of 48.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005370-62 Sponsor Protocol Number: ANAKIN-RA-DIABETES Start Date*: 2013-02-18
    Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA
    Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe...
    Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037740 RA LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005322-22 Sponsor Protocol Number: RV-MDS-PI-0550-REV/AZA Start Date*: 2012-06-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)
    Medical condition: Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002311 Anemia refractory LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003907-20 Sponsor Protocol Number: C16051 Start Date*: 2019-07-10
    Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit
    Full Title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refract...
    Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001888-78 Sponsor Protocol Number: CC-4047-MM-010 Start Date*: 2012-10-22
    Sponsor Name:Celgene Corporation
    Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Medical condition: Refractory multiple myeloma (MM) or relapsed and refractory MM.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) SE (Completed) NL (Completed) DE (Completed) FI (Completed) AT (Completed) GR (Completed) GB (Completed) DK (Completed) IT (Completed) BE (Completed) IE (Completed) NO (Completed) SK (Completed) SI (Completed) EE (Prematurely Ended) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000348-17 Sponsor Protocol Number: CSL842_3001 Start Date*: 2017-11-17
    Sponsor Name:CSL Behring LLC
    Full Title: A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of ...
    Medical condition: Refractory AMR in adult renal transplant participants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005843-21 Sponsor Protocol Number: KT-US-982-5968 Start Date*: 2022-02-08
    Sponsor Name:KITE PHARMA INC.
    Full Title: Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells
    Medical condition: B-cell malignancies and Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008978 Chronic lymphocytic leukemia refractory LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081514 Acute myeloid leukemia refractory LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063621 Acute lymphoblastic leukaemia recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006599 Burkitt's lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036714 Primary mediastinal large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009356-20 Sponsor Protocol Number: I-48-52030-223 Start Date*: 2009-06-25
    Sponsor Name:IPSEN NV
    Full Title: A PHASE II/III, MULTI-CENTRE, PROSPECTIVE, EXPLORATORY, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH REFRACTORY DIAR...
    Medical condition: Refractory diarrhea
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10012727 Diarrhea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000409-19 Sponsor Protocol Number: TOTAL Start Date*: 2018-05-08
    Sponsor Name:LYSARC
    Full Title: A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance
    Medical condition: Relapsed or refractory peripheral T-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042980 T-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042979 T-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001775-39 Sponsor Protocol Number: BDT-01-2011 Start Date*: 2011-09-20
    Sponsor Name:AZIENDA SANITARIA DELL'ALTO ADIGE - COMPRENSORIO SANITARIO DI BOLZANO
    Full Title: PHASE II MULTICENTER CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH...
    Medical condition: Relapsed or refractory active MM (according to the International Myeloma Working Group guidelines) after treatments containing bortezomib and lenalidomide or ineligible (intolerance or toxicity) to...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051381 Myeloma recurrence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000227-71 Sponsor Protocol Number: ITCC-059 Start Date*: 2016-09-02
    Sponsor Name:Erasmus Medical Center
    Full Title: A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
    Medical condition: pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) PT (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000302-37 Sponsor Protocol Number: RHMCAN1278 Start Date*: 2017-09-06
    Sponsor Name:University Hospital Southampton Foundation Trust
    Full Title: A phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies
    Medical condition: Relapsed or refractory B-Cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-002809-23 Sponsor Protocol Number: CV131-235 Start Date*: 2005-11-18
    Sponsor Name:Bristol-Myers Squibb SL
    Full Title: Electrophysiological effects of Irbesartan in patients with paroxysmal AF Efectos electrofisiológicos del Irbesartán en sujetos con FA paroxística
    Medical condition: Patients with paroxysmal atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005010-30 Sponsor Protocol Number: KTE-C19-104 Start Date*: 2017-09-27
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)
    Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) BE (Completed) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004087-40 Sponsor Protocol Number: PR-CS011 Start Date*: 2008-10-06
    Sponsor Name:Prospect Therapeutics, Inc
    Full Title: A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Relapsed or refractory diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012822 Diffuse large B-cell lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000603-16 Sponsor Protocol Number: HYPOXIC Start Date*: 2013-09-12
    Sponsor Name:University Medical Center Utrecht
    Full Title: HYPerbaric OXygen therapy for benign anastomotIC esophageal strictures: a pilot study
    Medical condition: Patients with benign recurrent and refractory esophageal anastomotic strictures.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005609-20 Sponsor Protocol Number: MK3475-B68 Start Date*: 2021-05-19
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B...
    Medical condition: Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080208 Classical Hodgkin lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) FR (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002584-33 Sponsor Protocol Number: CINC424C2301 Start Date*: 2017-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell tran...
    Medical condition: corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) AT (Completed) FR (Completed) NO (Completed) SE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PT (Completed) HU (Completed) BG (Completed) PL (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000821-22 Sponsor Protocol Number: XPORT-MM-028 Start Date*: 2020-05-07
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexametha...
    Medical condition: Penta-refractory multiple myeloma and triple-class refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-006170-28 Sponsor Protocol Number: E2007-G000-307 Start Date*: 2008-09-15
    Sponsor Name:Eisai Ltd
    Full Title: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-scalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy i...
    Medical condition: Epilepsy: refractory partial seizures with or without secondary generalisation
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) AT (Completed) BE (Completed) PT (Completed) LT (Completed) NL (Completed) HU (Completed) FR (Completed) GB (Completed) SE (Completed) EE (Completed) LV (Completed) DK (Completed) IT (Completed) DE (Completed) FI (Completed) BG (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001923-38 Sponsor Protocol Number: KTE-C19-108 Start Date*: 2019-05-06
    Sponsor Name:Kite Pharma, Inc
    Full Title: Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    20.1 100000004864 10008978 Chronic lymphocytic leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 13:32:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA